Non-radioactive method to measure organ blood flow

非放射性方法测量器官血流量

• 批准号: 6336142
• 负责人: CHRISTOPHER P REINHARDT
• 金额: $ 46.25万
• 依托单位: BIOPAL, INC
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-02-15 至 2003-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6336142
• 关键词: activation analysis; blood flow measurement; cardiovascular disorder diagnosis; coronary occlusion /thrombosis; microcapsule; nonradiation isotope effect; stable isotope; stable isotope diagnosis; technology /technique development

DESCRIPTION (Verbatim from the Applicant's Abstract): The hypothesis tested during Phase I was that stable isotope-labeled microspheres and neutron activation technology can be used to measure regional organ perfusion within in vivo models. We successfully proved our hypothesis and demonstrated concept feasibility. The results of our Phase I study show that blood flow values obtained from stable isotope-labeled microspheres compare favorably to values obtained from radioactive microspheres. Phase 11 will develop new products and systems to support our microsphere product-line and advance its commercial, potential. Phase 11 will develop new microsphere labels using enriched isotopes to maximize the sensitivity of the assay and to minimize the production of activation products of the element. We will also extend this work to label additional sizes of microspheres for uses in other areas of perfusion research. We will characterize label concentration and evaluate microsphere label stability over a range of conditions. In addition, Phase II will develop a novel automated Compton-suppression, coincidence-counting system that will improve the sensitivity and specificity of spectrographic analysis of complex gamma-ray spectra following neutron activation. Finally, we will design and characterize an automated sample delivery system to neutron activate large numbers of samples. Construction will be a Phase III project funded by BioPAL. PROPOSED COMMERCIAL APPLICATION: Neutron activation-based assays can simultaneously track multiple stable-isotope labeled research products within in vivo system. This ability is of high interest to the biomedical research community. No current technology can provide this level of versatility.

描述（来自申请人摘要的逐字记录）：假设检验 在第一阶段，稳定的同位素标记的微球和中子 激活技术可用于测量在脑内的局部器官灌注。 体内模型我们成功地证明了我们的假设和演示的概念 可行性我们的I期研究结果表明， 从稳定的同位素标记的微球获得的结果与 从放射性微球中获得。第11阶段将开发新产品， 系统，以支持我们的微球产品线，并推进其商业， 潜力第11阶段将使用富集同位素开发新的微球标记 为了使测定的灵敏度最大化并使 元素的活化产物。我们还将这项工作扩展到标签 用于灌注研究的其它领域的其它尺寸的微球。 我们将表征标记浓度并评估微球标记 在一系列条件下的稳定性。此外，第二阶段将开发一个 新型自动康普顿抑制，符合计数系统，将 提高络合物光谱分析的灵敏度和特异性 中子活化后的伽马射线谱。最后，我们将设计和 表征中子活化大的自动样品输送系统 样本数量。建设将是一个由BioPAL资助的第三阶段项目。 拟定商业应用： 基于中子活化的测定可以同时追踪体内系统内多种稳定同位素标记的研究产品。这种能力是高度感兴趣的生物医学研究界。目前没有任何技术可以提供这种水平的多功能性。